If your weight has stopped moving on semaglutide or tirzepatide, the most likely explanation is that your body did exactly what the biology predicts. A plateau is not evidence that the medication stopped working, and it is not evidence that you did something wrong. Every weight loss intervention ever studied ends in a plateau, including bariatric surgery. What differs is how long the losing phase lasts and how much comes off first. Knowing why the plateau arrives is what tells you whether to change something or leave it alone.
Why a plateau happens
The intuitive explanation is that your metabolism crashed. That is mostly not what the research shows.
A 2024 analysis by Kevin Hall at the National Institutes of Health modelled weight loss for diet restriction, semaglutide, tirzepatide and gastric bypass, and found the plateau is driven mainly by appetite rather than by a collapse in energy expenditure. As you lose weight, a feedback circuit gradually pushes hunger up. Energy intake creeps back toward energy expenditure even when your effort has not changed at all. The plateau is the point where rising appetite meets the appetite suppression the drug provides, and the two cancel out (Hall, Obesity, 2024).
The same analysis found that semaglutide, tirzepatide and gastric bypass all weaken that appetite feedback substantially compared with dieting alone. That is why these medications outperform willpower, and why the plateau still arrives. Feeling hungrier at month ten than at month two is not a character failure and not the drug wearing off. It is the predicted physiology.
When it usually shows up
In Hall’s modelling, weight loss from diet restriction alone flattens within roughly twelve months. With semaglutide 2.4 mg or tirzepatide 10 mg, the plateau is pushed out to roughly twenty four months. Most well known trials ran shorter than that, which is part of why it catches people out. If you are eight or twelve months in and the scale has slowed, you are on schedule.
The dose ceiling is real, and it is a limitation
There is a point past which there is simply no more medication to give. The FDA label for Wegovy sets the usual maintenance dose of the injection at 2.4 mg once weekly, with 1.7 mg as the alternative for people who cannot tolerate the higher dose (FDA prescribing information). For Zepbound, the label states plainly that the maximum dose is 15 mg once weekly (FDA prescribing information).
At the ceiling, escalating further is not something a prescriber can honestly offer. Anyone who offers it anyway has stepped outside approved dosing, and the safety and efficacy data do not follow them there. This is a genuine limit of the current medications, better heard plainly than dressed up as a workaround.
Check body composition before you call it a plateau
The scale is a poor instrument here. Losing fat while holding muscle can look like a flat line for weeks, and that distinction matters more on these medications than most people realise. A recent review of body composition during incretin therapy reported that lean mass makes up a substantial share of the weight lost, on the order of forty percent with semaglutide over sixty eight weeks. It recommends 1.2 to 1.6 grams of protein per kilogram of body weight per day and resistance training on at least two non-consecutive days per week, started at the beginning of treatment rather than added later, because lean mass lost early may not come back (Healthcare, 2026).
If your weight is flat but your waist is still shrinking and you are getting stronger, nothing is wrong. There is more in how to lose fat without losing muscle.
When a plateau is worth investigating
Most plateaus are expected. A few are signals. Raise it with your clinician if any of these apply:
- You started a medication known to cause weight gain, including some antidepressants, antipsychotics, steroids and beta blockers.
- You have untreated or undertreated thyroid disease.
- You have untreated sleep apnea, or you snore heavily and wake unrefreshed.
- Your weight is climbing, not just flat.
- You are eating so little that you feel cold, exhausted and are losing strength. Undereating on an appetite suppressant is a real risk, not a theoretical one.
These are worth testing for rather than assuming.
Where the evidence is genuinely thin
There is no good trial evidence that diet breaks, reset weeks, drug holidays or subtherapeutic dosing schedules break a plateau. These circulate widely online and none has been properly tested in this setting. Switching between agents is sometimes a reasonable clinical decision, but data on switching specifically at the point of plateau is limited. Anyone selling a protocol that reliably breaks a GLP-1 plateau is ahead of the evidence.
Stopping is the one option with clear data, and it is not encouraging. In the STEP 1 extension, participants regained a mean of 11.6 percentage points of body weight in the year after semaglutide was withdrawn, roughly two thirds of what they had lost (Diabetes, Obesity and Metabolism, 2022). More in what happens after you stop.
Red flags that need a clinician, not a plan change
- Severe or persistent abdominal pain, particularly pain radiating to the back
- Right upper abdominal pain after fatty meals, jaundice or pale stools
- Persistent vomiting or an inability to keep fluids down
- A new neck lump, hoarseness or difficulty swallowing
- Any planned surgery or procedure involving anaesthesia, which your care team needs to know about in advance
How we handle it
At MetaHealth a plateau is a data point, not an emergency. That means looking at body composition rather than weight alone, checking thyroid function and the full medication list, confirming protein and resistance training are genuinely in place, and saying so directly when you have simply reached the plateau this treatment produces. Sometimes the plan should change. Often the right call is to protect what you already gained. More on our medical weight loss page.
Medically reviewed by Krishna Borges, MSN, APRN, FNP-C. This article is for general education and is not a substitute for individual medical advice.